(R)-Fadrozole is primarily used as a selective aromatase inhibitor, which plays a significant role in the treatment of hormone-dependent cancers, particularly breast cancer. By inhibiting the aromatase enzyme, it reduces the production of estrogen, thereby slowing the growth of estrogen-sensitive tumors. This makes it a valuable component in hormone therapy for postmenopausal women with breast cancer. Additionally, (R)-Fadrozole is utilized in research settings to study the effects of estrogen suppression in various biological processes. Its specificity and potency make it a useful tool in understanding the role of aromatase in both normal and pathological conditions, contributing to advancements in endocrinology and oncology research.